Climb Bio (NASDAQ:CLYM) Coverage Initiated at Wedbush

Research analysts at Wedbush began coverage on shares of Climb Bio (NASDAQ:CLYM) in a note issued to investors on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $12.00 price target on the stock. Wedbush’s target price indicates a potential upside of 67.13% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Piper Sandler began coverage on shares of Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating on the stock. HC Wainwright increased their price objective on Climb Bio from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Finally, Wall Street Zen cut Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.60.

Climb Bio Trading Down 2.8%

Shares of CLYM opened at $7.18 on Thursday. The firm has a fifty day moving average price of $5.20 and a 200-day moving average price of $3.32. The firm has a market capitalization of $489.53 million, a P/E ratio of -8.07 and a beta of -0.25. Climb Bio has a 12-month low of $1.05 and a 12-month high of $7.59.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). Analysts predict that Climb Bio will post -1.57 earnings per share for the current year.

Insider Transactions at Climb Bio

In other Climb Bio news, Director Ra Capital Management, L.P. acquired 213,099 shares of Climb Bio stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $2.18 per share, with a total value of $464,555.82. Following the completion of the purchase, the director directly owned 3,294,856 shares of the company’s stock, valued at approximately $7,182,786.08. This represents a 6.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased 321,672 shares of company stock worth $779,626 over the last 90 days. Company insiders own 0.80% of the company’s stock.

Institutional Trading of Climb Bio

Several hedge funds and other institutional investors have recently bought and sold shares of CLYM. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in Climb Bio in the third quarter valued at about $29,000. Virtu Financial LLC purchased a new position in Climb Bio in the fourth quarter valued at about $43,000. Qube Research & Technologies Ltd bought a new position in Climb Bio in the second quarter worth about $43,000. Finally, Blair William & Co. IL bought a new position in Climb Bio in the fourth quarter worth about $44,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Wedbush initiated coverage with an “outperform” rating and a $12 price target, providing analyst endorsement that implies significant upside from current levels. Wedbush Initiates Coverage
• Positive Sentiment: Robert W. Baird raised its price target from $9 to $12 and assigned an “outperform” rating, echoing bullish analyst sentiment and adding upward price-target momentum. Baird Price Target Raise
• Positive Sentiment: Company operational update: dosing completed in a Phase 1 subcutaneous study of budoprutug, multiple clinical trials ongoing (pMN, ITP, SLE) with initial data expected H1–H2 2026, ongoing enrollment in CLYM116 Phase 1; management says cash runway extends into 2028 — these milestones support medium-term value if data readouts are positive. Press Release
• Neutral Sentiment: Short-interest reports in early March show zero reported short positions and a 0.0 days-to-cover figure, which appears to be a data anomaly (NaN/inconsistent reporting) and likely has limited informational value until clarified.
• Negative Sentiment: Climb reported Q4 EPS of ($0.26), missing the consensus ($0.20) by $0.06 — a clear near-term negative that likely pressured the stock as investors digest lower-than-expected profitability metrics. Earnings Release

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.